Osimertinib Improved Survival in Lung Cancer Trial
The ADAURA trial showed significantly higher eight-year survival rates for patients receiving adjuvant osimertinib.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should medical guidelines prioritize treatments showing higher survival rates in long-term clinical trials?
Researchers presented eight-year survival data from the phase 3 ADAURA trial in 2026, revealing improved outcomes for patients with resected EGFR-mutated non-small cell lung cancer. The study found that patients treated with osimertinib experienced higher survival rates compared to those who received a placebo.
Why it matters
These long-term findings demonstrate the enduring benefit of adjuvant osimertinib therapy in preventing recurrence and extending life for patients with specific genetic mutations in lung cancer. The data offers critical evidence for clinicians managing early-stage disease following surgical resection.
In the ADAURA trial, the 8-year overall survival rate reached 79% for those on osimertinib compared to 64% for the placebo group. Researchers observed a hazard ratio of 0.52 in the overall population of 682 randomized patients.
The details
Patients in the trial were treated with three years of adjuvant osimertinib or a placebo, with or without prior chemotherapy, following the surgical removal of stage IB to IIIA non-small cell lung cancer. The analysis, based on a data cutoff of May 4, 2026, confirmed that survival benefits persisted for participants throughout the median follow-up period of over 93 months.
Timeline
May 4, 2026 was the cutoff date for the ADAURA trial data analysis.
The findings were presented in 2026 at the World Conference on Lung Cancer.
The Big Picture
The ADAURA trial has become a benchmark for assessing adjuvant therapies in lung cancer, and these results further confirm the long-term efficacy of targeting specific mutations. This study marks a departure from historical treatment standards that lacked targeted systemic therapy for resected non-small cell lung cancer.
This data reinforces the potential survival advantages of targeted adjuvant therapy for patients diagnosed with resected EGFR-mutated non-small cell lung cancer. Patients should discuss these long-term results and their specific EGFR status with their oncology care team.
The takeaway
These findings underscore the importance of genetic testing for patients with early-stage lung cancer to determine eligibility for targeted therapies. Long-term follow-up remains essential for understanding how such treatments impact survival and recurrence in the years following surgery.
Further reading
Learn more about the latest research in the Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Should medical guidelines prioritize treatments showing higher survival rates in long-term clinical trials?
